We rank companies based on fund manager, research analyst and news sentiment
AGIO stock icon

Agios Pharmaceuticals
AGIO

$29.51
3.66%
 

About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Employees: 386

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

236% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 11

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

20% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 49

18% more funds holding

Funds holding: 141 [Q3] → 167 (+26) [Q4]

0.6% more ownership

Funds ownership: 102.77% [Q3] → 103.37% (+0.6%) [Q4]

7% less call options, than puts

Call options by funds: $4.55M | Put options by funds: $4.9M

9% less capital invested

Capital invested by funds: $1.42B [Q3] → $1.29B (-$135M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$28
5%
downside
Avg. target
$33
13%
upside
High target
$42
42%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
JP Morgan
Tessa Romero
2%upside
$30
Neutral
Maintained
23 Feb 2024
RBC Capital
Gregory Renza
42%upside
$42
Outperform
Maintained
16 Feb 2024
Goldman Sachs
Salveen Richter
5%downside
$28
Neutral
Maintained
3 Nov 2023

Financial journalist opinion